CSPC Innovation Pharmaceutical Co Ltd Class A (300765) - Net Assets
Based on the latest financial reports, CSPC Innovation Pharmaceutical Co Ltd Class A (300765) has net assets worth CN¥2.80 Billion CNY (≈ $409.04 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.28 Billion ≈ $918.42 Million USD) and total liabilities (CN¥3.48 Billion ≈ $509.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300765 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.80 Billion |
| % of Total Assets | 44.54% |
| Annual Growth Rate | 16.18% |
| 5-Year Change | -15.23% |
| 10-Year Change | 388.67% |
| Growth Volatility | 43.79 |
CSPC Innovation Pharmaceutical Co Ltd Class A - Net Assets Trend (2014–2025)
This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. Also explore 300765 asset base for the complete picture of this company's asset base.
Annual Net Assets for CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2025)
The table below shows the annual net assets of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2025. For live valuation and market cap data, see CSPC Innovation Pharmaceutical Co Ltd Cl market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.80 Billion ≈ $409.04 Million |
-37.83% |
| 2024-12-31 | CN¥4.50 Billion ≈ $657.90 Million |
-18.01% |
| 2023-12-31 | CN¥5.48 Billion ≈ $802.37 Million |
+39.02% |
| 2022-12-31 | CN¥3.94 Billion ≈ $577.16 Million |
+19.61% |
| 2021-12-31 | CN¥3.30 Billion ≈ $482.55 Million |
+22.73% |
| 2020-12-31 | CN¥2.69 Billion ≈ $393.18 Million |
+11.24% |
| 2019-12-31 | CN¥2.42 Billion ≈ $353.44 Million |
+141.69% |
| 2018-12-31 | CN¥999.35 Million ≈ $146.24 Million |
+30.31% |
| 2017-12-31 | CN¥766.93 Million ≈ $112.23 Million |
+34.07% |
| 2016-12-31 | CN¥572.02 Million ≈ $83.70 Million |
-8.74% |
| 2015-12-31 | CN¥626.83 Million ≈ $91.72 Million |
+16.69% |
| 2014-12-31 | CN¥537.16 Million ≈ $78.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CSPC Innovation Pharmaceutical Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 458.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.04 Billion | 38.95% |
| Common Stock | CN¥1.40 Billion | 52.66% |
| Other Components | CN¥223.71 Million | 8.39% |
| Total Equity | CN¥2.67 Billion | 100.00% |
CSPC Innovation Pharmaceutical Co Ltd Class A Competitors by Market Cap
The table below lists competitors of CSPC Innovation Pharmaceutical Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dongxing Sec Co Ltd
SHG:601198
|
$6.24 Billion |
|
Zhejiang Longsheng Group Co Ltd
SHG:600352
|
$6.25 Billion |
|
Enel Chile S.A
SN:ENELCHILE
|
$6.25 Billion |
|
Ramsay Health Care Ltd
AU:RHC
|
$6.25 Billion |
|
Castellum AB
ST:CAST
|
$6.24 Billion |
|
Lithia Motors Inc
NYSE:LAD
|
$6.23 Billion |
|
Chailease Holding Co Ltd
TW:5871
|
$6.23 Billion |
|
Peric Special Gases Co. Ltd. A
SHG:688146
|
$6.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CSPC Innovation Pharmaceutical Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,730,544,275 to 2,667,343,683, a change of -1,063,200,592 (-28.5%).
- Net loss of 241,125,740 reduced equity.
- Dividend payments of 36,427,720 reduced retained earnings.
- Other comprehensive income decreased equity by 342,613,300.
- Other factors decreased equity by 443,033,832.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-241.13 Million | -9.04% |
| Dividends Paid | CN¥36.43 Million | -1.37% |
| Other Comprehensive Income | CN¥-342.61 Million | -12.84% |
| Other Changes | CN¥-443.03 Million | -16.61% |
| Total Change | CN¥- | -28.50% |
Book Value vs Market Value Analysis
This analysis compares CSPC Innovation Pharmaceutical Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 66.81x to 15.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥0.45 | CN¥30.37 | x |
| 2015-12-31 | CN¥0.71 | CN¥30.37 | x |
| 2016-12-31 | CN¥0.65 | CN¥30.37 | x |
| 2017-12-31 | CN¥0.87 | CN¥30.37 | x |
| 2018-12-31 | CN¥1.12 | CN¥30.37 | x |
| 2019-12-31 | CN¥2.18 | CN¥30.37 | x |
| 2020-12-31 | CN¥2.27 | CN¥30.37 | x |
| 2021-12-31 | CN¥2.46 | CN¥30.37 | x |
| 2022-12-31 | CN¥2.94 | CN¥30.37 | x |
| 2023-12-31 | CN¥3.78 | CN¥30.37 | x |
| 2024-12-31 | CN¥2.67 | CN¥30.37 | x |
| 2025-12-31 | CN¥1.92 | CN¥30.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CSPC Innovation Pharmaceutical Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.23%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 2.35x
- Recent ROE (-9.04%) is below the historical average (14.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 20.15% | 16.63% | 0.78x | 1.55x | CN¥54.52 Million |
| 2015 | 18.50% | 15.58% | 0.78x | 1.53x | CN¥53.10 Million |
| 2016 | 36.11% | 23.20% | 0.92x | 1.69x | CN¥149.38 Million |
| 2017 | 25.41% | 18.90% | 0.91x | 1.47x | CN¥118.22 Million |
| 2018 | 22.59% | 18.05% | 0.89x | 1.40x | CN¥124.76 Million |
| 2019 | 11.35% | 21.74% | 0.44x | 1.19x | CN¥32.56 Million |
| 2020 | 11.20% | 22.76% | 0.45x | 1.10x | CN¥32.02 Million |
| 2021 | 11.95% | 21.26% | 0.49x | 1.14x | CN¥64.29 Million |
| 2022 | 18.45% | 27.65% | 0.57x | 1.16x | CN¥332.72 Million |
| 2023 | 8.23% | 17.11% | 0.34x | 1.41x | CN¥-93.65 Million |
| 2024 | 1.44% | 2.71% | 0.33x | 1.61x | CN¥-319.33 Million |
| 2025 | -9.04% | -11.23% | 0.34x | 2.35x | CN¥-507.86 Million |
Industry Comparison
This section compares CSPC Innovation Pharmaceutical Co Ltd Class A's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $603,020,681
- Average return on equity (ROE) among peers: 8.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CSPC Innovation Pharmaceutical Co Ltd Class A (300765) | CN¥2.80 Billion | 20.15% | 1.25x | $6.24 Billion |
| Shenzhen Shenbao Industrial Co Ltd (000019) | $1.01 Billion | 7.41% | 0.22x | $1.24 Billion |
| Hainan Pearl River Holdings Co Ltd (000505) | $581.64 Million | 0.71% | 0.96x | $640.30 Million |
| Xiwang Foodstuffs Co Ltd (000639) | $1.22 Billion | 9.64% | 0.53x | $320.65 Million |
| Nanfang Black Sesame Group Co Ltd (000716) | $138.53 Million | -4.55% | 4.80x | $566.73 Million |
| CNFC Overseas Fishery Co Ltd (000798) | $272.30 Million | 36.10% | 1.40x | $498.43 Million |
| Henan Shuanghui Investment & Development Co Ltd (000895) | $780.28 Million | 7.22% | 0.51x | $14.06 Billion |
| Xinjiang Chalkis Co Ltd (000972) | $-254.89 Million | 0.00% | 0.00x | $435.65 Million |
| Zhengzhou Qianweiyangchu Food Co Ltd (001215) | $582.34 Million | 13.15% | 0.64x | $666.24 Million |
| Qingdao Foods Co Ltd (001219) | $273.68 Million | 14.03% | 0.19x | $450.52 Million |
| Shandong Oriental Ocean Sci-Tech Co Ltd (002086) | $1.43 Billion | 2.91% | 0.85x | $587.64 Million |
About CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. The company offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dyphylline, theobromine, pentoxifylline, and doxofylline; and health food product… Read more